FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017012921> ?p ?o ?g. }

• W2017012921 endingPage "30S" @default.
• W2017012921 startingPage "21S" @default.
• W2017012921 abstract "The objective of this study was to evaluate the efficacy and safety of botulinum toxin type A for the treatment of glabellar lines. Patients with moderate or severe glabellar lines at maximal frown received intramuscular injections of placebo or 20 U of botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) distributed among five injection sites (one in the procerus muscle and two in each corrugator supercilii). Follow-up assessments were performed at 7, 30, 60, 90, and 120 days after injections. Efficacy measures were the physician's rating of glabellar line severity at maximal frown and at rest (none, mild, moderate, or severe) and the patient's global assessment of changes in glabellar lines, from +4 (100 percent better) to -4 (100 percent worse). A total of 273 patients were enrolled (botulinum toxin, 202 patients; placebo, 71 patients). All except five patients (botulinum toxin, two patients; placebo, three patients) completed the study. For the physician's rating at maximal frown, the responder rate (percentage of patients with severity ratings of none or mild in follow-up evaluations) for the botulinum toxin group peaked at 77 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). For the patient's assessment, the responder rate (percentage of patients with scores of +2 or more) for the botulinum toxin group peaked at 89 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). Rates of adverse events were similar for the two groups. The only adverse event with an incidence of >/=5 percent was headache (botulinum toxin, 11 percent; placebo, 20 percent). The incidence of blepharoptosis was 1 percent for the botulinum toxin group. Botulinum toxin type A was remarkably safe and effective in reducing glabellar lines." @default.
• W2017012921 created "2016-06-24" @default.
• W2017012921 creator A5000630505 @default.
• W2017012921 creator A5005646253 @default.
• W2017012921 creator A5028812886 @default.
• W2017012921 creator A5071114904 @default.
• W2017012921 creator A5079641537 @default.
• W2017012921 date "2003-10-01" @default.
• W2017012921 modified "2023-10-17" @default.
• W2017012921 title "Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar Lines" @default.
• W2017012921 cites W1965278980 @default.
• W2017012921 cites W1966165000 @default.
• W2017012921 cites W1969772266 @default.
• W2017012921 cites W1977815227 @default.
• W2017012921 cites W1978910356 @default.
• W2017012921 cites W2006651872 @default.
• W2017012921 cites W2033132384 @default.
• W2017012921 cites W2048364855 @default.
• W2017012921 cites W2060774155 @default.
• W2017012921 cites W2082127529 @default.
• W2017012921 cites W2087719977 @default.
• W2017012921 cites W2094416353 @default.
• W2017012921 cites W2157760932 @default.
• W2017012921 cites W2159755590 @default.
• W2017012921 cites W4226153170 @default.
• W2017012921 cites W4254915344 @default.
• W2017012921 cites W4363610867 @default.
• W2017012921 cites W43666815 @default.
• W2017012921 doi "https://doi.org/10.1097/01.prs.0000076504.79727.62" @default.
• W2017012921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12973229" @default.
• W2017012921 hasPublicationYear "2003" @default.
• W2017012921 type Work @default.
• W2017012921 sameAs 2017012921 @default.
• W2017012921 citedByCount "162" @default.
• W2017012921 countsByYear W20170129212012 @default.
• W2017012921 countsByYear W20170129212013 @default.
• W2017012921 countsByYear W20170129212014 @default.
• W2017012921 countsByYear W20170129212015 @default.
• W2017012921 countsByYear W20170129212016 @default.
• W2017012921 countsByYear W20170129212017 @default.
• W2017012921 countsByYear W20170129212018 @default.
• W2017012921 countsByYear W20170129212019 @default.
• W2017012921 countsByYear W20170129212020 @default.
• W2017012921 countsByYear W20170129212021 @default.
• W2017012921 countsByYear W20170129212022 @default.
• W2017012921 countsByYear W20170129212023 @default.
• W2017012921 crossrefType "journal-article" @default.
• W2017012921 hasAuthorship W2017012921A5000630505 @default.
• W2017012921 hasAuthorship W2017012921A5005646253 @default.
• W2017012921 hasAuthorship W2017012921A5028812886 @default.
• W2017012921 hasAuthorship W2017012921A5071114904 @default.
• W2017012921 hasAuthorship W2017012921A5079641537 @default.
• W2017012921 hasConcept C126322002 @default.
• W2017012921 hasConcept C141071460 @default.
• W2017012921 hasConcept C142724271 @default.
• W2017012921 hasConcept C204787440 @default.
• W2017012921 hasConcept C27081682 @default.
• W2017012921 hasConcept C2777478456 @default.
• W2017012921 hasConcept C2991744798 @default.
• W2017012921 hasConcept C42219234 @default.
• W2017012921 hasConcept C71924100 @default.
• W2017012921 hasConceptScore W2017012921C126322002 @default.
• W2017012921 hasConceptScore W2017012921C141071460 @default.
• W2017012921 hasConceptScore W2017012921C142724271 @default.
• W2017012921 hasConceptScore W2017012921C204787440 @default.
• W2017012921 hasConceptScore W2017012921C27081682 @default.
• W2017012921 hasConceptScore W2017012921C2777478456 @default.
• W2017012921 hasConceptScore W2017012921C2991744798 @default.
• W2017012921 hasConceptScore W2017012921C42219234 @default.
• W2017012921 hasConceptScore W2017012921C71924100 @default.
• W2017012921 hasIssue "Supplement" @default.
• W2017012921 hasLocation W20170129211 @default.
• W2017012921 hasLocation W20170129212 @default.
• W2017012921 hasOpenAccess W2017012921 @default.
• W2017012921 hasPrimaryLocation W20170129211 @default.
• W2017012921 hasRelatedWork W2003938723 @default.
• W2017012921 hasRelatedWork W2029595472 @default.
• W2017012921 hasRelatedWork W2047967234 @default.
• W2017012921 hasRelatedWork W2066861358 @default.
• W2017012921 hasRelatedWork W2118496982 @default.
• W2017012921 hasRelatedWork W2364998975 @default.
• W2017012921 hasRelatedWork W2369162477 @default.
• W2017012921 hasRelatedWork W2439875401 @default.
• W2017012921 hasRelatedWork W4238867864 @default.
• W2017012921 hasRelatedWork W2525756941 @default.
• W2017012921 hasVolume "112" @default.
• W2017012921 isParatext "false" @default.
• W2017012921 isRetracted "false" @default.
• W2017012921 magId "2017012921" @default.
• W2017012921 workType "article" @default.